Study of Comparative Advantages of Chinese and Indian Pharmaceutical Industries under Globalization by YUE, Feifei & YUE, Yingming
MANAGEMENT SCIENCE AND ENGINEERING 
 Vol. 4, No. 4, 2010, pp. 82-86 
 www.cscanada.org                                 
   ISSN 1913-0341 [Print] 
ISSN 1913-035X [Online] 




Study of Comparative Advantages of Chinese and 







Abstract: The authors explore the background and major factors that have promoted the 
growth of Pharmaceutical industry in India. Government policy and globalization 
strategy have played critical roles in positioning India as a pharmaceutical powerhouse. 
China, facing similar challenges and opportunities in the global economy, could draw 
valuable lessons from India’s growth story. There are also synergy and strategic fit 
between the two emerging economy in the pharmaceutical industry  




Since India’s independence, its domestic companies have experienced significant growth. After five 
decades of development, India has become one of the most important sources of active ingredients and bulk 
drugs. Presently, it’s exporting to more than 100 countries in total. Its main export regions are US, Western 
Europe and Asia (especially China). Although China has a larger domestic market and enjoys phenomenal 
growth as well, India‘s expertise on regulatory compliance and process chemistry has given it competitive 
advantages in the global market. The article will discuss the factors that contributed to India’s success and 
identify some lessons that China could learn from this formidable competitor. The authors believe that four 
factors have contributed to India’s success: Government Policy, internationalization Strategy, Process 
expertise and regulatory expertise.  
 
 
1.  GOVERNMENT POLICY AND LOOSE IP PROTECTION 
LAW 
1.1  Beginning of Indian Pharmaceutical Industry 
Just after India’s independence in 1947, there was no pharmaceuticals industry to speak of. The Indian 
domestic pharmaceutical companies could not cater to the demands of the Indian population. Because of 
government price control, there was little incentive to expand production capacity either. In short, there was 
a crisis in public healthcare and getting access to affordable medicine. The government had two options at 
                                                 
1 Associate Professor, School of Management, University of Jinan, University of Jinan, Shandong Province, P. R. 
China. Email: sm_yueff@ujn.edu.cn. 
School of Management, University of Jinan, 250022    Jiwei Road No. 106, Jinan, Shandong Province, P.R. China 
2 Associate Director, 109 Meghan Lane, Madison, AL, 35758, US. 
*Received 20 July 2010; accepted 19 November 2010. 
YUE Fei-fei; YUE Ying-ming/Management Science and Engineering Vol.4 No.4, 2010 
     83
the time, either to import drugs in large quantities or to develop the local industry by relaxing IP rules. The 
Indian government opted for the latter solution. From 1970 onwards, instead of granting process and 
product patents, the new IPR regime began to recognize only process patents. 
 
1.2  Indian Patent Act of 1970 
The Indian Patent Act of 1970 increased the incentives for Indian firms as second innovators. The impact of 
the change in IPR was simply tremendous. Many Indian pharmaceutical firms were able to produce 
essential drugs like antibiotics with a heavy slashing of prices. Indian consumers revealed themselves to be 
price sensitive rather than being brand loyal to western brands. Most importantly, the public Indian 
healthcare system was finally able to stand up on its feet and there was a significant increase in the 
proportion of the poor who had access to basic drugs. Indian firms even entered into production contracts 
with the original multinational inventors, permitting them also to enjoy lower costs and a greater mark-up. 
India became an exporter of bulk drugs and final therapeutics, supplying many parts of the developing and 
developed world at lower costs. In 1970, the Indian market was clearly dominated by multinational firms 
and eight of the top ten firms were MNCs. After two decades following the 1970 Patent Act, Indian 
pharmaceutical industry was dominated by domestic firms and only four of the top ten firms were now 
multinational. By the mid 1980s most Indian pharmaceutical firms were producing bulk drugs and 
formulations for the domestic market and the leading domestic firms (e.g. Ranbaxy) had begun to explore 
markets in Asia and Africa.  
The Indian case study shows that in a developing country, with an excess demand and a significant 
technological retard in a knowledge intensive sector, a narrowing of the IPR regime can serve to create 
industrial competence and also increase welfare. The case study also shows that a narrowing or a loosening 
of the IPR might be welfare enhancing, if it leads to a greater quantity being produced and/or a lowering of 
price in the final market. It might be welfare enhancing even at a global level, if other developing countries 
are able to thereafter obtain the generic versions of the knowledge intensive commodity more easily or at 
lower prices. 
 
1.3  Government contribution 
In addition to establishing favorable policy and regulations, India government has been instrumental in 
setting up infrastructure for nascent industry and ensure sufficient industry clustering and knowledge 
diffusion. Take Hyderabad as an example, India government started India drug and pharmaceutical Limited 
(“IDPL”) and set up five plants and operations in Hyderabad area. The company has serves as an incubator 
for many new starts ups for the industry. Statistics shows that one third of the senior management from 
roughly two hundred biotech and pharmaceutical companies have worked in IDPL at some point of their 
career. Two of the founders of Dr. Reddy’s, one of the most successful companies, also came from IDPL. In 
addition to the industry enterprises, Hyderabad has roughly 40 institutions of higher learning. The 
prestigious India institute of Chemical technology and Center for cellular and Molecular biology are also 
based in the city. Because of the close proximity to suppliers and peer companies, it’s very easy for 
knowledge and skills to be diffused from one company to another.  
 
2.  REGULATORY COMPLIANCE AND CHEMISTRY 
EXPERTISE 
2.1  Familiarity with regulated market 
When it comes to US FDA approved plants, India easily surpassed China and other competitors. The total 
number of plants inspected and approved by FDA exceeds one hundred and is more than the total of 
combined plants in China and Italy. The larger number of approved plants is helping propel long-term 
growth for Indian drug makers. The approved sites would help the sector widen its presence in the global 
market by producing high-quality products within the country and in other regulated markets.   
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2.2  Superior Process Expertise 
In addition to regulatory compliance, India has developed very strong process chemistry expertise through 
many years of “reverse engineering” activities. India’s chemistry capabilities which have formed the 
foundation for its world class generics pharmaceutical industry are well applied in providing high end 
chemistry research services to support drug discovery. Medicinal chemistry services provided by Indian 
companies include the synthesis of building blocks, scaffolds and intermediates for generating analogues; 
compounds for assays and animal models and custom designed small molecules for Lead Generation and 
Lead Optimization. The sector’s leading players have been awarded multi-million contracts from the 
world’s leading pharmaceutical companies and set up facilities with many hundreds of chemists to deliver 
these projects over 3-5 year time periods. More recently Indian vendors are making deals with international 
companies whereby the undertake to perform lead generation and optimization for a raft of molecules not 
for a service fee but for milestone payments and royalties on the successful delivery of lead molecules to 
pre-clinical or even late stage clinical development. 
 
3.  INTERNATIONALIZATION STRATEGY  
3.1  Synergy creation  
In the last decade Indian pharmaceutical firms have emerged as most aggressive overseas investors of all 
Indian industries. Analysis of Indian firms’ internationalization strategies suggests that acquisition is 
preferred route of Indian firms’ international expansion compared with organic routes in advanced 
countries. The benefits are created through synergies formed by the product pipeline of Indian firms and 
assets provided by overseas firms. Indian firms have a large pipeline of products, cheap manufacturing 
facilities and an ambition to enter the advanced market of Europe and the US. However Indian firms lack 
distribution setup and high-end technological capabilities. Thus through acquisition Indian firms are 
generating synergies with their competitively priced products. 
 
3.2  Market Share Increase 
In addition to synergy creation, Indian firms are seeking to increase their market share by acquiring generic 
firms in advanced markets and creating business links with MNE pharmaceutical firms. This is clearly 
evident in NPILS’s acquisition of production facility of Pfizer in Scotland. NPIL has a contract for process 
development and scale up deal for Pfizer’s animal healthcare products. But with acquisition of Pfizer’s 
production facility in Scotland NPIL has emerged as the largest supplier in dollar terms as Pfizer has agreed 
to source from this facility for the next five years. Acquisition of big name Pharma facility gives Indian 
firms instant credibility and also access to advanced management concepts and process controls.  
 
3.3  Access to regulated market 
Although India is a low-cost location for drug manufacturing and process R&D, analysis suggests that 
Indian firms are acquiring assets in advanced countries to augment their current capabilities and set up 
business closer to customers. For example in the case of bulk drugs MNC firms are currently outsourcing 
work on intermediates to Indian firms but really reluctant in the case of outsourcing other work such as 
finding efficient processes for new or patent expired drugs even though Indian firms have excellent 
capabilities. Indian firms are responding to these challenges by setting up operations close to customers 
through acquisition of western firms in highly regulated advance market. Acquisition of UK based Avecia 
helps the company to fill a knowledge gap in early stage R&D works and bid for contracts from firms 
operating in advance countries. Customers in the advanced countries often have concerns with the 
intellectual IP protection status in India. By setting up shops in advanced countries not only fill the 
knowledge gap, it also helps alleviate concerns on IP protection. These acquisitions are providing access to 
customers who may not have done business with Indian firms. 
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3.4  Moving up the value chain 
By acquiring specific skills and technologies in advance markets, Indian firms are moving up the value 
chain. In high volume-low cost API market Indian firms are now facing competition from Chinese firms 
which can manufacture bulk drugs at a cheaper rate than Indian firms. Indian firms are using access to 
technology as a differentiating factor where competition on the basis of cost has limitation. Nicholas 
Piramal’s acquisition of Avecia or DRL’s acquisition of Trigenesis shows Indian firms efforts to move up 
the value chain by augmenting existing capabilities through acquisition. Avecia, Nicholas’s acquisition is 
able to make toxic products and other high value drugs such as hormones and owns a fermentation 
equipment to make drugs more efficiently. These drugs require a high quality of safety and containment and 
therefore they are highly-priced making them more profitable to innovators. DRL’s acquisition of Trigeneis 
gives company access to certain products and proprietary drug delivery technology platforms to develop a 
pipeline of drugs in the dermatology segment. One of Trigeneisis’s proprietary technologies takes care of 
major challenges faced in the formulation and delivery of drugs in the areas of oral, injectables, inhaled and 
topical delivery. 
 
4.  COMPARISON BETWEEN INDIA AND CHINA 
 
The global pharmaceutical industry is facing a number of challenges. Companies today need to pursue 
more efficient, cost-effective and productive ways to conduct their operations, whether in R&D or 
manufacturing. The key to a quick turnaround is to have drugs discovered quicker, developed faster, 
manufactured cheaper and marketed more widely. Among the emerging countries, China and India have 
risen rapidly in the global pharmaceutical outsourcing arena, as both countries possess the unique 
combination of low cost and quality service. The current global financial crisis has also enhanced the 
importance of these two countries to many drug companies around the world that are seeking cost 
reductions.   
 
4.1  Environment for patent protection 
As part of concession to WTO admission, both India and China has agreed to product patent protection and 
tougher enforcement of IP infringement. The improved IP protection environment has promoted R&D 
investment, both from domestic and direct foreign investments. Empirical evidence suggests that leading 
India pharmaceutical companies have increased their R&D investment significantly post-TRIPS. 
Companies, such as Dr. Reddy’s, Ranbaxy are moving aggressively into high-margin and high-risk disease 
areas. In comparison, the R&D funding in China is primarily driven by the central government and very 
small percentages are from private enterprise. To promote innovation by the private enterprise, China needs 
to develop a handful leading companies to effectively compete with their western and India counterparts. In 
China, top ten firms contribute to roughly 20% of total revenue compared with 50% in India. Although 
China has embarked on a industry consolidation through government guidance and GMP certification, the 
process is quite slow and premier pharmaceutical company with the statue of  Dr. Reddy’s and Ranbaxy has 
yet to emerge.  
 
4.2  Interaction between Indian and Chinese Pharmaceutical industries 
Over the past few years, there has been a growing engagement between India and China in the economic 
sphere, and this has extended to the pharmaceuticals and biotechnology sectors as well. While several 
major Indian pharmaceutical firms have set up joint ventures and production facilities in China, China has 
emerged as a very important supplier of APIs and bulk drugs for pharmaceuticals industry in India. As a 
source of India’s imports of medicinal and pharmaceutical products, China’s share is the highest, at 34.6 
percent in 2005-06, having risen from 6.2 percent in 1993-94. Correspondingly, as a destination for India’s 
exports of drugs, pharmaceuticals and fine chemicals, China’s share increased from 0.4 percent in 1993-94 
to 3.5 percent in 2005-06.  
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Because of the mutual economic dependency, India and China can enhance their levels of engagement 
and learn from each other.  Currently China only has 55 plants approved by FDA, compared with 100 
approved plants in India. The low approval rate is due to Chinese company’s unfamiliarity with rules. India 
pharmaceutical industry can provide valuable service by providing technical and regulatory support. Many 
Chinese companies are currently taking steps to implement GMP regulations and in the process of filing 
Drug Master Files (DMF). However, it will take time to be well-versed in European and US rules and 
regulations. India has extensive experience in supplying API and formulation products to the regulated 
market, China can benefit from their Indian counterparts in understanding and implementing GMP 
regulations. By setting up strategic partnerships with Chinese firms, India firms can benefit from China’s 
better infrastructure and access to vast majority of intermediates and APIs.  
 
4.3  Lesson learned from Indian’s international expansion 
India’s experience in international expansion can provide a lot of valuable lessons for Chinese firms in 
penetrating into western regulated market. Current high growth rate in Chinese domestic market is not 
sustainable. Once domestic market is saturated, China will have to look outside for market growth. India 
companies have set up a lot of good precedence in strategic alliance, joint venture, or asset acquisition in the 
industry. By setting up joint ventures or acquire assets in regulated market, India has increased its 
understanding in local regulatory affairs and alleviated concerns of intellectual property protection. Most 
importantly, India has successfully moved up value chain and is positioning itself in high-margin areas. 
Obviously, Challenges and opportunities faced by India firms during the international expansion may very 
well be repeated by Chinese firms tomorrow. It is recommended that China pharmaceutical industry study 
India’s experiences and lessons carefully and transforms itself into a leading player in the global 
pharmaceutical industry.  
 
5.  CONCLUSIONS 
 
The authors think that loose government patent policy has given birth to a very competitive Indian 
Pharmaceutical industry. Armed with extensive experience and expertise in process chemistry and 
regulatory compliance, India is moving aggressively into the international and regulatory market. By 
collaborating with Indian firms, domestic Chinese firms can benefit and strength it’s competitive 
positioning in the global market.  
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